Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

Part of paid clinical trials in Gaithersburg, Maryland.

Sponsor: AstraZeneca
Study ID: NCT07414134
Status: Completed

Conditions

Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Sex: ALL
Age: 40 Years - N/A
Healthy Volunteers: Not accepted

Interventions

BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL — DRUG
This is a real-world observational study evaluating the timing of BGF, post discharge.

Study Details

This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry® and Centers for Medicare \& Medicaid Services (CMS) 100% Medicare Fee for Service (FFS) database spanning from January 1, 2021 to the most recently available data (September 30th, 2024 for the MORE2 database, and December 31st, 2023 for the Medicare FFS database) will be used for this analysis. All patients will be required to present at least one prescription claim for BGF. Patients will also be required to show evidence of a qualifying severe COPD exacerbation event during the 180-day period preceding initiation of BGF. Index date will be set as the date of discharge from the qualifying severe exacerbation event.